Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Affiliations

Lori J. Goldstein: Department of Medical Oncology, The Hospital of Fox Chase Cancer Center
Raymond P. Perez: University of Kansas Medical Research Center
Denise Yardley: Tennessee Oncology
Linda K. Han: Indiana University Simon Cancer Center
James M. Reuben: Department of Hematopathology–Research, MD Anderson Cancer Center
Hui Gao: Department of Hematopathology–Research, MD Anderson Cancer Center
Susan McCanna: Research and Development, Dompé farmaceutici S.p.A.
Beth Butler: Research and Development, Dompé farmaceutici S.p.A.
Pier Adelchi Ruffini: Research and Development, Dompé farmaceutici S.p.A.
Yi Liu: The Methodist Hospital Research Institute
Roberto R. Rosato: The Methodist Hospital Research Institute
Jenny C. Chang: The Methodist Hospital Research Institute

Abstract

An amendment to this paper has been published and can be accessed via the original article.

ISSN: 1465-5411 (Print); 1465-542X (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://breast-cancer-research.biomedcentral.com/